2. Academic Validation
  3. A fourth case of Feingold syndrome type 2: psychiatric presentation and management

A fourth case of Feingold syndrome type 2: psychiatric presentation and management

  • BMJ Case Rep. 2014 Nov 12;2014:bcr2014207501. doi: 10.1136/bcr-2014-207501.
Hooman Ganjavi 1,  Victoria Mok Siu 2,  Marsha Speevak 3,  Penny Anne MacDonald 4
Affiliations

Affiliations

  • 1 Department of Psychiatry, University of Western Ontario, London, Ontario, Canada.
  • 2 Department of Paediatrics, University of Western Ontario, London, Ontario, Canada Department of Biochemistry, University of Western Ontario, London, Ontario, Canada.
  • 3 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
  • 4 Brain and Mind Institute, University of Western Ontario, London, Ontario, Canada Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada.
PMID: 25391829 DOI: 10.1136/bcr-2014-207501
Abstract

Feingold syndrome (FGLDS1) is an autosomal dominant disorder caused by mutations in the MYCN oncogene on the short arm of chromosome 2 (2p24.1). It is characterised by microcephaly, digital abnormalities, oesophageal and duodenal atresias, and often learning disability or mental retardation. In 2011, individuals sharing the skeletal abnormalities of FGLDS1 but lacking mutations in MYCN, were found to harbour hemizygous deletions of the MIR17HG gene on chromosome 13q31.3. These individuals share many of the characteristics of FGLDS1 except for gastrointestinal atresia. The condition was termed Feingold syndrome type 2 (FGLDS2). We describe the presentation and management of a fourth known case of FGLDS2 in an 18-year-old girl with microcephaly, short stature, mildly dysmorphic features, digital malformations and significant cognitive and psychiatric symptoms. Comparative genomic hybridisation array testing confirmed a 7.4 Mb microdeletion in chromosome region 13q31.1q.31.3 corresponding to the MIR17HG gene.

Figures